On Tuesday, Protagonist Therapeutics Inc (NASDAQ: PTGX) was 4.33% up from the session before settling in for the closing price of $75.25. A 52-week range for PTGX has been $33.31 – $93.25.
When this article was written, the company’s average yearly earnings per share was at -140.82%. With a float of $58.79 million, this company’s outstanding shares have now reached $62.11 million.
Protagonist Therapeutics Inc (PTGX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Protagonist Therapeutics Inc stocks. The insider ownership of Protagonist Therapeutics Inc is 5.51%, while institutional ownership is 110.87%. The most recent insider transaction that took place on Oct 10 ’25, was worth 979,480. In this transaction Director of this company sold 12,000 shares at a rate of $81.62, taking the stock ownership to the 5,130 shares. Before that another transaction happened on Oct 10 ’25, when Company’s Director proposed sale 12,000 for $67.04, making the entire transaction worth $804,480.
Protagonist Therapeutics Inc (PTGX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.54 earnings per share (EPS) during the time that was less than consensus figure (set at -0.53) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -140.82% per share during the next fiscal year.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators
You can see what Protagonist Therapeutics Inc (PTGX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.97. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.35. Likewise, its price to free cash flow for the trailing twelve months is 131.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.71, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach 0.06 in one year’s time.
Technical Analysis of Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc (NASDAQ: PTGX) saw its 5-day average volume 0.9 million, a negative change from its year-to-date volume of 1.01 million. As of the previous 9 days, the stock’s Stochastic %D was 56.99%.
During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 66.40%, which indicates a significant increase from 46.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 4.87 in the past 14 days, which was higher than the 2.55 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $65.28, while its 200-day Moving Average is $51.78. Nevertheless, the first resistance level for the watch stands at $79.93 in the near term. At $81.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $83.91. If the price goes on to break the first support level at $75.95, it is likely to go to the next support level at $73.38. The third support level lies at $71.97 if the price breaches the second support level.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats
There are 62,211K outstanding shares of the company, which has a market capitalization of 4.88 billion. As of now, sales total 434,430 K while income totals 275,190 K. Its latest quarter income was 5,550 K while its last quarter net income were -34,770 K.
